

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Michailidis
Date of last notice	12 July 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	John Michailidis & Helen Michailidis atf Michailidis Family Account
Date of change	18 November 2024
No. of securities held prior to change	Indirect: John Michailidis & Helen Michailidis atf Michailidis Family Account: 1,199,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025 1,000,000 Unlisted Options exercisable at \$0.10 ea expiring 9 July 2028
Class	Performance Rights
Number acquired	Indirect: Performance Rights 359,640

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Performance Rights: Nil
No. of securities held after change	Indirect: John Michailidis & Helen Michailidis atf Michailidis Family Account: 1,199,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025 1,000,000 Unlisted Options exercisable at \$0.10 ea expiring 9 July 2028 359,640 Performance Rights
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued Performance Rights following Shareholder approval at the Annual General Meeting held on 14 November 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only